Indegene

Indegene P/B

The P/B (Price-to-Book Ratio) of Indegene (INDGN.NS) as of Oct 21, 2026 is 3.63. In the previous year, P/B (Price-to-Book Ratio) was 4.35 — a change of -16.67% (lower).

P/B

3.63

YoY

-16.67%

Last updated:

P/B (Price-to-Book Ratio) of Indegene is 2026 3.63 . P/B (Price-to-Book Ratio) of Indegene was 2025 4.35 . It decreases by -16.67% lower compared to the previous year.

The Indegene P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2020
-108.70 INR
Jan 1, 2021
35.06 INR
Jan 1, 2022
14.90 INR
Jan 1, 2023
10.70 INR
Jan 1, 2024
7.96 INR
Jan 1, 2025
4.35 INR
Jan 1, 2026
3.63 INR
The Indegene P/B history
YEARP/BYoY
3.63-16.67%
4.35-45.36%
7.96-25.57%
10.70-28.19%
14.90-57.52%
35.06-132.26%
-108.70—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Indegene Stock analysis

What does Indegene do? Indegene Ltd generates revenue by providing digital-led commercialization services to life sciences companies, including biopharmaceutical, emerging biotech, and medical devices firms. The company assists these clients with drug development, clinical trials, regulatory submissions, pharmacovigilance, complaints management, and the sales and marketing of their products. This comprehensive support structure allows Indegene to serve as a key partner in the end-to-end commercialization process for its diverse client base within the life sciences sector. The company monetizes its offerings through specialized solution segments such as Omnichannel Activation, which helps life sciences companies leverage a digital first approach for optimizing the last-mile promotion of biopharmaceutical products and medical devices to healthcare professionals across multiple channels. Additionally, Enterprise Commercial Solutions primarily involves assisting life sciences companies with their digital marketing operations, further expanding the company's service portfolio and revenue streams. Revenue is also derived from Enterprise Medical Solutions, where Indegene establishes centers of excellence to consolidate large scale regulatory and medical operations for its clients. The company rounds out its business model by offering enterprise clinical solutions and consultancy services, ensuring a holistic service delivery model that addresses various operational needs of its customers in the life sciences industry. Indegene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Indegene stock

P/B (Price-to-Book Ratio) of Indegene is 3.63 in 2026.

P/B (Price-to-Book Ratio) of Indegene changed from 4.35 to 3.63, representing a -16.67% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Indegene since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Indegene with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Indegene

All Key Metrics — Indegene